UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
March 13, 2020
Commission File Number: 001 - 38178
Zealand Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Sydmarken 11
2860 Søborg (Copenhagen)
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-Fx Form 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
The audited consolidated financial statements of Zealand Pharma A/S (the “Company”) and its subsidiaries as of and for the year ended December 31, 2019 are included in the Zealand Pharma A/S Annual Report filed as exhibit 99.1(a) to this Form 6-K and incorporated by reference herein. A copy of the announcement issued by the Company on March 11, 2020 is filed as Exhibit 99.1 to this Form 6-K and incorporated by reference herein.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Zealand Pharma A/S |
| | | |
| | By: | /s/ Matthew Dallas |
| | | | |
| | | Name: | Matthew Dallas |
| | | Title: | Chief Financial Officer |
Date: March 13, 2020
EXHIBIT INDEX
